PH12020551728A1 - Stat3 inhibitors - Google Patents
Stat3 inhibitorsInfo
- Publication number
- PH12020551728A1 PH12020551728A1 PH12020551728A PH12020551728A PH12020551728A1 PH 12020551728 A1 PH12020551728 A1 PH 12020551728A1 PH 12020551728 A PH12020551728 A PH 12020551728A PH 12020551728 A PH12020551728 A PH 12020551728A PH 12020551728 A1 PH12020551728 A1 PH 12020551728A1
- Authority
- PH
- Philippines
- Prior art keywords
- stat3 inhibitors
- same
- stat3
- inhibitors
- fibrosis
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101150099493 STAT3 gene Proteins 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 abstract 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000007881 chronic fibrosis Effects 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polymerisation Methods In General (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659872P | 2018-04-19 | 2018-04-19 | |
| US201962793491P | 2019-01-17 | 2019-01-17 | |
| PCT/US2019/028135 WO2019204614A1 (en) | 2018-04-19 | 2019-04-18 | Stat3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12020551728A1 true PH12020551728A1 (en) | 2021-06-14 |
Family
ID=68240338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12020551728A PH12020551728A1 (en) | 2018-04-19 | 2020-10-19 | Stat3 inhibitors |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11826315B2 (https=) |
| EP (2) | EP3773537B1 (https=) |
| JP (1) | JP7411315B2 (https=) |
| KR (1) | KR102792113B1 (https=) |
| CN (1) | CN112367984B (https=) |
| AU (1) | AU2019255755B2 (https=) |
| BR (1) | BR112020021329A2 (https=) |
| DK (1) | DK3773537T3 (https=) |
| ES (1) | ES2911428T3 (https=) |
| HU (1) | HUE059318T2 (https=) |
| IL (1) | IL278112B2 (https=) |
| MX (1) | MX2020011065A (https=) |
| MY (1) | MY207195A (https=) |
| PH (1) | PH12020551728A1 (https=) |
| PL (1) | PL3773537T3 (https=) |
| PT (1) | PT3773537T (https=) |
| SG (1) | SG11202010347XA (https=) |
| WO (1) | WO2019204614A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7411315B2 (ja) * | 2018-04-19 | 2024-01-11 | トゥヴァルディ セラピューティクス，インク． | Ｓｔａｔ３阻害剤 |
| CN114761405A (zh) * | 2019-11-29 | 2022-07-15 | 南京明德新药研发有限公司 | 抗hbv的1,7-萘啶类化合物 |
| JP2023504194A (ja) * | 2019-12-03 | 2023-02-01 | ベイラー カレッジ オブ メディスン | インスリン耐性における使用方法のための治療化合物 |
| JP2023520273A (ja) * | 2020-01-24 | 2023-05-17 | トゥヴァルディ セラピューティクス，インク． | 治療化合物、製剤、およびその使用 |
| CN114286684B (zh) * | 2020-07-27 | 2024-01-05 | 华中科技大学 | 与stat3相关的疾病的预防和/或治疗 |
| AR128676A1 (es) * | 2022-03-01 | 2024-06-05 | Tvardi Therapeutics Inc | Compuestos terapéuticos, formulaciones, uso y método de preparación |
| US20250170079A1 (en) * | 2022-03-04 | 2025-05-29 | Tvardi Therapeutics, Inc. | Combinations of stat-inhibitors and immune checkpoint inhibitors for the treatment and/or management of cancer |
| CA3254067A1 (en) | 2022-06-15 | 2023-12-21 | Tvardi Therapeutics, Inc. | STAT3 INHIBITOR MEDICINES |
| TW202412749A (zh) * | 2022-07-21 | 2024-04-01 | 美商特梵迪治療股份有限公司 | 治療性化合物、調配物、及其用途 |
| EP4633620A1 (en) * | 2022-12-12 | 2025-10-22 | Tvardi Therapeutics, Inc. | Stat3 inhibitors for use in the treatment of non-viral liver cancer |
| WO2025184497A1 (en) * | 2024-02-29 | 2025-09-04 | Tvardi Therapeutics, Inc. | Stat3 inhibitors for use in the treatment of cancer |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4279909A (en) | 1980-02-13 | 1981-07-21 | Fujisawa Pharmaceutical Co., Ltd. | Antiallergic method |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6492428B1 (en) | 2000-07-26 | 2002-12-10 | The Picower Institute For Medical Research | Compounds having MIF antagonist activity |
| US6197749B1 (en) | 1997-10-29 | 2001-03-06 | Ajinomoto Co., Inc. | Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes |
| CA2413878A1 (en) | 2000-06-20 | 2001-12-27 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| JP2005522457A (ja) | 2002-02-26 | 2005-07-28 | ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート | 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害 |
| WO2005026134A1 (en) | 2003-09-17 | 2005-03-24 | Novartis Ag | Organic compounds |
| US20050287664A1 (en) | 2004-05-27 | 2005-12-29 | Ming-Ji Fann | Cellular proliferation control factors |
| US20060148715A1 (en) | 2004-12-20 | 2006-07-06 | Baylor College Of Medicine | Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands |
| US20100035793A1 (en) | 2005-07-27 | 2010-02-11 | Cheh Peng Lim | Modulators |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| CA2636909A1 (en) | 2006-01-13 | 2007-07-26 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production with tanshinones |
| WO2007136858A2 (en) | 2006-05-19 | 2007-11-29 | H. Lee Moffitt Cancer Center & Research Institute | Small molecule inhibitors of stat3 with anti-tumor activity |
| US20090264353A1 (en) | 2007-10-19 | 2009-10-22 | Santaris Pharma A/S | Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease |
| HRP20160625T1 (hr) * | 2007-09-10 | 2016-08-12 | Boston Biomedical, Inc. | Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka |
| WO2009038784A1 (en) | 2007-09-21 | 2009-03-26 | Amgen Inc. | Triazole fused heteroaryl compounds as p38 kinase inhibitors |
| EP2299999B1 (en) * | 2008-06-04 | 2017-08-16 | Baylor College Of Medicine | Stat3 inhibitors |
| GB2463514C (en) | 2008-09-11 | 2018-09-26 | Galapagos Nv | Imidazolidine compounds and uses therefor |
| WO2010080581A2 (en) | 2008-12-19 | 2010-07-15 | The Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Valproic acid, derivatives, analogues, and compositions including same and methods for their therapeutic use |
| US8557805B2 (en) | 2008-12-29 | 2013-10-15 | Takeda Pharmaceutical Company Limited | Fused ring compound and use thereof |
| US9891213B2 (en) | 2009-01-12 | 2018-02-13 | The Board Of Trustees Of The Leland Stanford Junior University | Granulocyte-based methods for detecting and monitoring immune system disorders |
| CA2781706A1 (en) * | 2009-11-24 | 2011-06-03 | The Ohio State University | Transcription factor inhibitors and related compositions, formulations and methods |
| FR2962649B1 (fr) | 2010-07-19 | 2025-10-24 | Conservatoire Nat Arts Et Metiers | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide |
| US20140371188A1 (en) | 2011-11-23 | 2014-12-18 | University Of Iowa Research Foundation | Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy |
| EP2708535A1 (en) | 2012-05-11 | 2014-03-19 | Les Laboratoires Servier | Agents for treating disorders involving modulation of ryanodine receptors |
| CN102766103B (zh) * | 2012-07-24 | 2014-12-10 | 齐鲁制药有限公司 | 2-硫代-4-胺基-1-萘酚衍生物、其制备方法和用途 |
| AU2014290363B2 (en) * | 2013-07-18 | 2019-02-21 | Baylor College Of Medicine | Methods and compositions for treatment of fibrosis |
| AU2014290368B2 (en) | 2013-07-18 | 2019-07-11 | Baylor College Of Medicine | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia |
| US20150031714A1 (en) | 2013-07-18 | 2015-01-29 | Baylor College Of Medicine | Methods and compositions for prevention of allergic reaction |
| WO2017083719A1 (en) * | 2015-11-13 | 2017-05-18 | William Marsh Rice University | Transition metal free methods of synthesis of biaryl compounds |
| JP7411315B2 (ja) * | 2018-04-19 | 2024-01-11 | トゥヴァルディ セラピューティクス，インク． | Ｓｔａｔ３阻害剤 |
| US11026905B2 (en) * | 2018-04-19 | 2021-06-08 | Tvardi Therapeutics, Inc. | STAT3 inhibitors |
| JP2023520273A (ja) * | 2020-01-24 | 2023-05-17 | トゥヴァルディ セラピューティクス，インク． | 治療化合物、製剤、およびその使用 |
-
2019
- 2019-04-18 JP JP2020558021A patent/JP7411315B2/ja active Active
- 2019-04-18 PL PL19788688T patent/PL3773537T3/pl unknown
- 2019-04-18 MX MX2020011065A patent/MX2020011065A/es unknown
- 2019-04-18 BR BR112020021329-2A patent/BR112020021329A2/pt unknown
- 2019-04-18 PT PT197886880T patent/PT3773537T/pt unknown
- 2019-04-18 WO PCT/US2019/028135 patent/WO2019204614A1/en not_active Ceased
- 2019-04-18 ES ES19788688T patent/ES2911428T3/es active Active
- 2019-04-18 US US17/048,602 patent/US11826315B2/en active Active
- 2019-04-18 MY MYPI2020005483A patent/MY207195A/en unknown
- 2019-04-18 KR KR1020207033270A patent/KR102792113B1/ko active Active
- 2019-04-18 CN CN201980041259.1A patent/CN112367984B/zh active Active
- 2019-04-18 DK DK19788688.0T patent/DK3773537T3/da active
- 2019-04-18 HU HUE19788688A patent/HUE059318T2/hu unknown
- 2019-04-18 EP EP19788688.0A patent/EP3773537B1/en active Active
- 2019-04-18 EP EP22161820.0A patent/EP4070790A1/en active Pending
- 2019-04-18 AU AU2019255755A patent/AU2019255755B2/en active Active
- 2019-04-18 SG SG11202010347XA patent/SG11202010347XA/en unknown
-
2020
- 2020-10-18 IL IL278112A patent/IL278112B2/en unknown
- 2020-10-19 PH PH12020551728A patent/PH12020551728A1/en unknown
-
2023
- 2023-10-05 US US18/481,522 patent/US20240058284A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN112367984A (zh) | 2021-02-12 |
| ES2911428T3 (es) | 2022-05-19 |
| MY207195A (en) | 2025-02-05 |
| KR102792113B1 (ko) | 2025-04-04 |
| KR20210011925A (ko) | 2021-02-02 |
| JP7411315B2 (ja) | 2024-01-11 |
| US20240058284A1 (en) | 2024-02-22 |
| US11826315B2 (en) | 2023-11-28 |
| AU2019255755A1 (en) | 2020-12-03 |
| BR112020021329A2 (pt) | 2021-04-27 |
| IL278112B2 (en) | 2023-07-01 |
| JP2021521243A (ja) | 2021-08-26 |
| EP3773537A1 (en) | 2021-02-17 |
| US20210114980A1 (en) | 2021-04-22 |
| IL278112B1 (en) | 2023-03-01 |
| PL3773537T3 (pl) | 2022-05-23 |
| PT3773537T (pt) | 2022-04-19 |
| AU2019255755B2 (en) | 2024-07-25 |
| MX2020011065A (es) | 2021-01-20 |
| EP4070790A1 (en) | 2022-10-12 |
| SG11202010347XA (en) | 2020-11-27 |
| HUE059318T2 (hu) | 2022-11-28 |
| CA3097403A1 (en) | 2019-10-24 |
| IL278112A (https=) | 2020-12-31 |
| EP3773537B1 (en) | 2022-03-23 |
| CN112367984B (zh) | 2024-05-10 |
| EP3773537A4 (en) | 2021-05-26 |
| DK3773537T3 (en) | 2022-04-25 |
| WO2019204614A1 (en) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551728A1 (en) | Stat3 inhibitors | |
| ZA202007007B (en) | Mcl-1 inhibitors | |
| MX2020012731A (es) | Inhibidores de kras g12c y metodos para su uso. | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2021006731A (es) | Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico. | |
| EP3938354A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | |
| EP4025590A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| MX2021006326A (es) | Inhibidores de pcna. | |
| EP3847283A4 (en) | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF MANAGED CANCER | |
| SG11202110674XA (en) | Compound, method and pharmaceutical composition for modulating expression of dux4 | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| ZA202310843B (en) | Chromene derivatives as inhibitors of tcr-nck interaction | |
| EP3856352A4 (en) | Methods of treatment of cancer comprising cdc7 inhibitors | |
| EP3842042A4 (en) | PHARMACEUTICAL COMPOSITION WITH A METAL ION-BONDED IONIC COMPOUND FOR THE TREATMENT OF CANCER | |
| EP3930705A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| IL288953A (en) | Pharmaceutical compounds, kits and methods for the treatment of cancerous tumors | |
| EP3968785A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | |
| EP3970745A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS | |
| EP3897642A4 (en) | METHODS OF TREATMENT OF INFLAMMATION | |
| WO2020033019A3 (en) | Novel mct4 inhibitors and uses thereof | |
| EP3773585A4 (en) | Compositions and methods for treating cancer | |
| EP4074316A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | |
| EP4077690A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| MX2020009813A (es) | Composiciones y metodos para tratar el prurito. |